摘要
中期因子(midkine,MDK)是一种肝素结合生长因子,在维持正常组织功能以及介导疾病发展中都发挥重要作用。MDK在多种人类恶性肿瘤中高表达,并在癌症的生长、增殖、存活、转移、血管生成以及化疗抵抗过程中发挥重要功能。MDK不仅可以作为癌症诊断、治疗以及预后的生物标志物,还可以用于监测癌症治疗过程中的效果以及病人的反应,以MDK为临床靶点的抑制剂研究也在MDK高表达癌症中大量开展。本文系统地总结了MDK在癌症发生发展过程中的生物学作用及其参与的相关信号通路,并且进一步探讨了以此为基础的肿瘤标志物以及癌症个体化治疗的潜在靶点,旨在为以MDK为靶点指导癌症的临床诊疗提供依据。
Midkine(MDK),a heparin-binding growth factor,plays critical roles in normal tissue and disease development.It is reported to be overexpressed in many human malignancies,which participates in various biological processes of cancer,including cell growth,proliferation,survival,metastasis,angiogenesis and chemotherapeutic resistance.Recently,increasing studies have shown that MDK can not only act as a biomarker for the diagnosis,therapy and prognosis of cancer,but also can be used for surveilling the efficiency and response to cancer therapy.Furthermore,emerging studies have focused on the MDK inhibitors used for the therapy of MDK-overexpressed cancers.In this review,we systematically summarize the current findings that elucidate the biological function and the related signaling pathways of MDK in the tumorigenesis and development of cancer,and further explore the clinical implications of MDK as a biomarker in individualized treatment of carcinoma,which may provide a basis for MDK to function as a potential target in the diagnosis or treatment of cancer.
作者
刘玉婷
王奕婷
白晓彦
LIU Yuting;WANG Yiting;BAI Xiaoyan(Medical College of Dalian University,Dalian 116622,China)
出处
《生命的化学》
CAS
2021年第8期1692-1700,共9页
Chemistry of Life
基金
国家自然科学基金项目(81802758)。
作者简介
第一作者:刘玉婷,E-mail:1406776681@qq.com;通信作者:白晓彦,E-mail:baixiaoyan719@163.com。
